![](https://investorshub.advfn.com/uicon/656581.png?cb=1524143925)
Wednesday, October 10, 2018 8:15:37 PM
First commercial-scale production and material revenues to commence from
MXC Investigational Medicinal Product (IMP)
• MXC’s Medicinal Cannabis based IMP, CannEpilTM is now available for supply in
Australia under the Authorised Prescriber Scheme
• Authorisation has been granted by the TGA to specialist prescribers who are now
authorised to supply CannEpilTM to patients in Australia
• Authorisation follows recent Human Research Ethics Committee endorsement
from St Vincent’s Hospital Melbourne for the use of CannEpilTM in the treatment
of adult patients with drug-resistant epilepsy
• Represents a major milestone for MXC, validating and confirming its seed-topharma
strategy with the start of commercial supply of its first IMP offering
• The Company expects this to initially generate $1 million in annualised revenue
from the initial base of approximately 100 patients
• CannEpilTM is expected to be available for supply in Australia by December 2018
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM